Dr MacSweeney talks preventing Alzheimer’s with the Daily Express

Re:Cognition Health’s CEO & Medical Director discusses a ground-breaking clinical trial designed to stop the progression of Alzheimer’s disease

Dr Emer MacSweeney, a leading Consultant Neuroradiologist, shared her optimism for the new study, which will enable individuals to take control of their own health and influence their future in the fight against Alzheimer’s disease.

Gene could make people at a higher risk of developing Alzheimer’s

The Generation Study is screening thousands of healthy participants aged between 60-75 years at Re:Cognition Health Clinics in the UK, all of whom show no sign of cognitive decline. Volunteers will have a swab taken from their cheek in order to identify individuals who carry a specific gene. This gene could make them a higher risk of developing Alzheimer’s disease. Those who carry the APOE4 gene could be eligible to participate in the 5-8 year long Generation Program.

For the first time the opportunity exists for those at risk to gain early access to these new medicines to prevent the disease occurring in the first place or slow it downDr Emer MacSweeney

New Alzheimer’s treatment could prevent the formation of plaques in the brain

The APOE4 gene can increase the risk of developing Alzheimer’s disease. Plaque formation could be responsible for the development of Alzheimer’s disease. The Generation Program is investigating whether a new medication could prevent amyloid-β protein plaques from forming in the brain. These plaques can start forming by as much as 20 years before symptoms of Alzheimer’s disease begin to present. Find out more by selecting one of the buttons below




Back To All News